Novel Challenges and Therapeutic Options for Pulmonary Embolism and Deep Vein Thrombosis

Guest Editors:

Dr. Giacomo Boccuzzi
Division of Cardiology, Department of Medicine, San Giovanni Bosco Hospital, ASL Città di Torino, 10100 Turin, Italy

Dr. Luca Franchin
Division of Cardiology, Department of Medicine, San Giovanni Bosco Hospital, ASL Città di Torino, 10100 Turin, Italy

Deadline for manuscript submissions:
closed (1 October 2023)

Message from the Guest Editors

Venous thromboembolism, clinically presenting as deep vein thrombosis or pulmonary embolism, is the third most frequent acute cardiovascular syndrome.

In this clinical setting, the effects of partial or total occlusion of the pulmonary vascular bed could lead to very different clinical presentations and syndromes, ranging from cardiogenic shock needing hemodynamic support and reperfusion to respiratory failure and chronic pulmonary hypertension. One of the most challenging parts of venous thromboembolism management is the selection of the appropriate treatment according to the risk of the patient. Prediction of the recurrence of future events is still difficult in this scenario. In this regard, a comprehensive evaluation by a pulmonary embolism response team (PERT) is frequently needed to offer a personalized approach.

The aim of this issue is to evaluate the role of new options both medical or interventional for the treatment of pulmonary embolism or deep vein thrombosis as well as new tools for risk stratification such as machine learning or artificial intelligence.

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us